Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

2924results about How to "Reduce spread" patented technology

Pd-1 binding proteins

The present invention features PD-1 binding proteins, a subset of which inhibits binding of PD-L1 to the PD-1 receptor. These binding proteins can be employed to modulate the immune system through the manipulation of the PD-1 signaling pathway, enhancing host immunity to treat infections and cancer.
Owner:MERCK SHARP & DOHME LLC

Method and apparatus for automatically detecting sensitive information, applying policies based on a structured taxonomy and dynamically enforcing and reporting on the protection of sensitive data through a software permission wrapper

The present invention relates to the automatic detection of sensitive digital information, and the identification methods, application and enforcement of information security policies for digital information controlled through a software permission wrapper throughout the useful life of the information. This invention includes a unique taxonomy that defines the policies and rules regarding how the information is controlled automatically throughout its useful lifecycle based on the type of information, the stage of the information lifecycle, the user / group role accessing the information, the locality of the information, and the expected threats to the information. The taxonomy is maintained in a database that associates information security control policies and actions to sensitive data. These policies are enforced through a software permission wrapper that is used to encapsulate sensitive digital information. The software permission wrapper is used to control access and enforce digital rights to the information based on the taxonomy based policies for that information. The permission wrapper can automatically change the protection of the information based on pre-defined protection states that can automatically enforce discretionary access control rights to the sensitive information controlled in the permission wrapper. The changes to the level of protection occur dynamically based on changes in user locality, stage of information lifecycle, and user / group role and the detection of threats. In addition, there is provided an internal audit capability describing what actions the user has performed, where the data is located, with whom and how the data has been shared.
Owner:ENCRYPTX CORP

Virtual second line hybrid network communication system

A system and method for routing a telephone call on a PSTN network to a data device. The present invention utilizes an automatic call processing system that has a one number location service. A called party provides a calling profile that is stored in the automatic call processing (ACP) system. When a call is placed to a telephone number that is assigned to the called party, the call is routed to the ACP system. The ACP system calls each of the numbers of the calling profile for that called party until that party is reached. At least one of the destinations in the calling profile is a logical address for a data network. The automatic call processing system recognizes the logical address and queries a directory to determine if an IP address has been registered in the directory for the logical address of the called party. If the called party is using a data device that is logged on the Internet, an IP telephony agent, such as an IP telephony client running on the data device, registers the IP address of the data device together with the logical address of the caller. If the ACP system determines if an IP address is registered with the directory, the ACP system will direct the call to an Internet telephony gateway. The Internet telephony gateway encodes and packetizes the voice information for transmission over the data network to the data device.
Owner:VERIZON PATENT & LICENSING INC

Electromagnetic photonic catheter for reducing restenosis

The method of vascular treatment for restenosis or vulnerable plaque after an invasive procedure, such as for example angioplasty, stenting with or without drug coating, or drug delivery, comprises: inserting a catheter or hollow guide wire to the treatment location; delivering light through the catheter in the wavelength range of about 700–2500 nm; and moving the light to treat the affected region.
Owner:STONE GREGG W +5

Stent with polymeric coating

InactiveUS20040034409A1Effectively suppress the restenosis-triggering factorsReduce spreadPharmaceutical containersPretreated surfacesPercent Diameter StenosisPolymer
The invention concerns an implantable stent (10) with an at least portion-wise polymeric coating (16). The coating material is admittedly intended to bond to known materials but by virtue of its properties it is intended to enjoy improved compatibility and reduce inflammatory and proliferative processes which can lead to restenosis. That is achieved in that the polymeric coating (16) in the implantable condition after production and sterilization contains poly-L-lactide of a mean molecular weight of more than 200 kDa.
Owner:BIOTRONIK

Nonvolatile programmable resistor memory cell

InactiveUS20080001172A1High oxygen ion mobilityImprove response timeSemiconductor devicesPhysicsOxide
A nonvolatile programmable resistance memory cell comprising a high-mobility ion conductor and a method for fabricating the same are provides. The memory cell comprises of a first and second electrode and a reversible and persistent programmable resistance structure connecting the first and second electrode. The resistance is modifiable by altering the ionic distribution of a high-mobility oxygen ion conductor region. As an alternate embodiment, the memory cell further includes a transition-metal oxide region.
Owner:IBM CORP

Microcapsules and processes for making the same using various polymers and chitosans

A microcapsule having a mean diameter of from about 0.1 to about 5 mm, a membrane and a matrix containing at least one active principle wherein the microcapsule is the product of the process comprising the steps of (a) forming an aqueous matrix by heating an aqueous solution comprised of a gel former, an anionic polymer selected from the group consisting of a salt of alginic acid and an anionic chitosan derivative and active principle; (b) adding the aqueous matrix to an aqueous solution of chitosan.
Owner:COGNIS IP MANAGEMENT GMBH

EphA2 monoclonal antibodies and methods of use thereof

InactiveUS20040028685A1Decrease contactStable interactionOrganic active ingredientsFungiTubular networkLymphatic Spread
The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. In one embodiment, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and agonizes EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels. In other embodiments, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and inhibits cancer cell colony formation in soft agar, inhibits tubular network formation in three-dimensional basement membrane or extracellular matrix preparation, preferentially binds to an EphA2 epitope that is exposed on cancer cells but not non-cancer cells, and / or has a low Koff, thereby, inhibiting tumor cell growth and / or metastasis. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.
Owner:MEDIMMUNE LLC

Wireless indoor communications using antenna arrays

InactiveUS6895253B1High data rate communicationIncrease power marginData switching by path configurationDiversity/multi-antenna systemsData transmissionPower margin
A wireless communication system and method includes antenna arrays at both the transmitter and receiver having a plurality of elements for very high data rate communication. Phased array antennas or directive fixed beam antennas are used with a beamwidth in azimuth and elevation less than 30° to increase the power margin and to decrease the delay spread of signals at the receiver to permit wireless data communications at high data rates in closed environments, for example, bursty transmissions and isochronous communications. The wireless communication system is capable of data transmission rates which exceed 1 Gbps with propagation losses of up to at least 60 dB relative to one meter.
Owner:LUCENT TECH INC

Feed additives for animals: prevention of foot and mouth disease

The present invention relates to feed additives for cloven-hooved animals. The invention provides methods for making a biological compositions comprising yeast cells that can improve the immune functions of such animals such that the incidence of foot and mouth disease is reduced. The invention also relates to methods for manufacturing the biological compositions, and methods of using the biological compositions as feed additives.
Owner:ULTRA BIOTECH

Targeted drug delivery using EphA2 or EphA4 binding moieties

The present invention relates to methods and compositions designed for the treatment, management, or prevention of a hyperproliferative cell disease, particularly cancer. The methods of the invention comprise the administration of an effective amount of a composition that targets cells expressing an Eph family receptor tyrosine kinase, such as EphA2 or EphA4, for the treatment, management, or prevention of hyperproliferative diseases, particularly cancer. In one embodiment, the method of the invention comprises administering to a subject a composition comprising an EphA2 or EphA4 targeting moiety attached to a delivery vehicle, and one or more therapeutic or prophylactic agents that treat or prevent a hyperproliferative disease, where the therapeutic or prophylactic agents are operatively associated with the delivery vehicle. In another embodiment, the method of the invention comprises administering to a subject a composition comprising a nucleic acid comprising a nucleotide sequence encoding an EphA2 or EphA4 targeting moiety and a therapeutic or prophylactic agent that treats or prevents a hyperproliferative disease. In yet another embodiment, the method of the invention comprises administering to a subject a composition comprising an EphA2 or EphA4 targeting moiety and a nucleic acid comprising a nucleotide sequence encoding an agent that treats or prevents a hyperproliferative disease, where the nucleic acid is operatively associated with the delivery vehicle. Pharmaceutical compositions are also provided by the present invention.
Owner:MEDIMMUNE LLC

Methods and kits for the inhibition of hyperplasia in vascular fistulas and grafts

A method for inhibiting hyperplasia at an anastomotic junction of a vascular fistula or vascular graft comprises exposing the anastomotic junction to vibrational energy at a mechanical index and for a time sufficient to inhibit hyperplasia. Kits are described comprising the catheter or a probe suitable for performing the methods together with instructions for use setting forth the methods. The methods and kits are particularly suitable for treating anastomotic junctions formed to provide vascular access for hemodialysis, hemofiltration, and the like. The methods and kits are also suitable for treating other vascular grafts, such as those formed during cardiac bypass graft surgery, vascular repair, and the like.
Owner:PHARMASONICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products